Clinical Trials

Analysis of T cells from melanoma patients uncovers characteristics leading to cancer regression

CCR researchers used state-ot-the-art analytic techniques to determine characteristics of cells used in effective adoptive T cell therapy (ACT) in patients with advanced melanoma. This new information opens the door to manufacturing these cells in the laboratory and using them in immunotherapy for common cancers, including liver, breast, prostate, and colon cancer.

Clinical trial evaluates therapy for adults with relapsed/refractory HCL

Robert J. Kreitman, M.D., Senior Investigator in the Laboratory of Molecular Biology, is leading a study of a treatment for hairy cell leukemia (HCL). The goal of this study is to determine the overall rate of response to binimetinib, an MEK inhibitor, in patients with HCL who do not have a BRAF gene mutation.

Treatment for women with advanced, untreated cervical cancer tested in new clinical trial

Women 18 and older with previously untreated advanced cervical cancer may be eligible to participate in a clinical trial at the NIH Clinical Center. Christian S. Hinrichs, M.D., Senior Investigator in the Genitourinary Malignancies Branch, is leading a study of a treatment called induction immunotherapy that uses the patient’s own T cells (immune cells) to attack their cancer cells.

Clinical trial studies drug combination for EGFR-mutated adenocarcinomas

Adults with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer that has transformed to small cell lung cancer or a neuroendocrine tumor may be eligible to participate in a clinical trial at the NIH Clinical Center. Anish Thomas, M.B.B.S., M.D., NIH Lasker Clinical Research Scholar in the Developmental Therapeutics Branch, is leading a trial testing a drug combination to treat these kinds of tumors.

Clinical trial evaluates therapy for advanced or metastatic solid tumors

Marijo Bilusic, M.D., Ph.D., Associate Research Physician in the Genitourinary Malignancies Branch, is leading NCI’s participation in a multicenter study for adults with advanced or metastatic solid (non-blood) tumors that have not responded to standard treatments. This phase 1 study will evaluate a therapy, NC410, for any serious side effects and determine the best dose that will achieve an antitumor response.

Clinical trial studies modified treatment regimen for patients with B-ALL

B-cell acute lymphoblastic leukemia (B-ALL) is a fast-growing type of blood cancer in which too many B cells multiply in the bone marrow and blood. Haneen Shalabi, D.O., Assistant Research Physician in the Pediatric Oncology Branch, is leading a study looking at a different way of preparing patients for bone marrow transplant after they have received treatment for B-ALL.

Clinical trial to test drug for cancer patients with weakened immune systems

Cancer survivors age 60 and older have weakened immune systems, often caused by cancer treatments. Investigators want to see if a drug, NT-I7, is able to boost the response to vaccines in patients who otherwise may not be able to respond.

Japan approves photoimmunotherapy for head and neck cancer

Promising clinical trials have led to the regulatory approval of the Bioblade® Laser System and Akalux® IV Infusion 250mg in Japan. This device and drug combination was developed under an investigational treatment platform based on a cancer therapy called photoimmunotherapy.

New clinical trial studies stem cell transplant for primary immunodeficiency diseases

Dennis D. Hickstein, M.D., Senior Investigator in the Immune Deficiency Cellular Therapy Program is leading a study that uses new DNA technology that speeds up the process of screening for primary immunodeficiency diseases (PIDs) and finding an acceptable donor match for hematopoietic stem cell transplant (HSCT).

Clinical trial studies therapy for people with prostate or kidney cancer

James L. Gulley, M.D., Ph.D., Chief of the Genitourinary Malignancies Branch, is leading the National Cancer Institute’s participation in a clinical trial of an experimental drug called JNJ-63898081. The goal of this multicenter study is to find out if the drug is safe to use in humans and to determine the optimal dose for the second phase of the study.

Breadcrumb